Molecular Testing Continues to Predict Treatment Efficacy in Ovarian Cancer
Bradley J. Monk, MD, FACS, FACOG, discusses the importance of helping patients make informed decisions about their care options and the future role of antibody-drug conjugate targets in the biomarker testing arena.
Streamlined Genomic Testing Platforms Are Taking on A Bigger Role in Cancer Care
Genetic testing has afforded oncologists with the opportunity to identify patients who may have a higher risk of developing cancer and identify actionable mutations to allow patients to receive targeted therapy and have their long-term treatment plan mapped out at diagnosis.
Dr. Monk on the Need for Molecular Testing in Ovarian Cancer
Bradley J. Monk, MD, FACS, FACOG, discusses the importance of molecular testing in ovarian cancer.
Dr. Schwartzberg on the Use of Myriad Genomic Testing in Cancer Care
Lee S. Schwartzberg, MD, FACP, discusses the utilization of genomics in cancer care.
Ribociclib Plus Endocrine Therapy Improves PFS and OS in Elderly Patients With HR+/HER2– Breast Cancer
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
2 Clarke Drive Cranbury, NJ 08512